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Abstract:  
Psychiatrists and psychotherapists in the U.S.A. (1970s-1985) and Switzerland (1988-
1993) used MDMA legally to enhance the effectiveness of psychotherapy. Early reports 
suggest its usefulness in treating trauma-related disorders. Recently, encouraging re-
sults from the first completed pilot study of MDMA-assisted psychotherapy for PTSD 
were published. In this study, designed to test safety and efficacy of MDMA-assisted 
psychotherapy in patients with treatment-resistant PTSD, 12 patients were enrolled in 
a randomized, double-blind, active-placebo controlled trial using a low dose (25 mg 
plus 12.5 mg supplemental dose) and a full dose of MDMA (125 mg plus 62.5 mg sup-
plemental dose). MDMA was administered during 3 experimental sessions inter-
spersed with weekly non-drug psychotherapy sessions. Outcome measures were the 
Clinician-Administered PTSD Scale (CAPS) and Posttraumatic Diagnostic Scale (PDS). 
Patients were assessed at baseline, three weeks after the second and third MDMA 
session (end of treatment), at two month and one year follow-up.  
MDMA-assisted psychotherapy can be safely administered in a clinical setting. No 
drug-related serious adverse events occurred. Statistically significant reductions in 
CAPS scores were not shown (p=0.066), though there was clinically and statistically 
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significant self-report (PDS) improvement (p=0.014). CAPS scores improved further at 
one-year follow-up. Three MDMA sessions were more effective than two (p=0.016). 
Keywords:  
Methylenedioxymethamphetamine, MDMA, MDMA-assisted psychotherapy, psycho-
therapy, posttraumatic stress disorder, PTSD, entactogen 
Introduction: 
Posttraumatic stress disorder (PTSD) is a common problem in everyday medical prac-
tice and a major and costly public health problem all over the world. Lifetime preva-
lences in the general population range from below 1 % in European countries (Perko-
nigg et al. 2000, Hepp et al. 2005) up to an average of 8% in countries such as the USA 
(Breslau et al. 1991, Kessler et al. 1995) although more recent surveys in the Nether-
lands and Switzerland now show rising rates of 7.4% in adults, and 4.2% in adolescents 
respectively (de Vries and Olff 2011, Landolt et al. 2012, submitted). In specific popula-
tions (e.g. soldiers returning from military service) prevalence can be much higher 
(Hoge et al 2004). Psychotherapy has been recognized to be the most effective form of 
treatment for PTSD (van Etten et al. 1998). First-line treatments are exposure-based 
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therapies such as Cognitive Behavior Therapy (CBT), Prolonged Exposure (PE), Cogni-
tive Processing Therapy (CPT) or Eye Movement Desensitization and Reprocessing 
(EMDR) (Cloitre 2009, Benedek et al 2009, Foa et al. 2009). While demonstrating effi-
cacy for some patients, studies of CBT show high drop-out rates (20%) and limited ef-
fects on PTSD symptoms with up to 58% of study completers still meeting PTSD diag-
nosis after treatment and only 32-66% reaching a good level of end-state functioning 
(Schnyder 2005, Foa 2009). Despite better understanding and growing efficacy of exist-
ing psychotherapies, PTSD often remains a chronic illness with high rates of psychiatric 
and medical comorbidity (Jacobsen et al. 2001, McFarlane 2010) and suicidality 
(Panagioti et al. 2012). Serotonergic agents such as SSRIs and SNRIs are often used to 
treat PTSD and comorbid disorders or for patients unable to undergo psychotherapy. 
The only two FDA-approved drugs for this indication, sertraline and paroxetine (Brady 
et al. 2000, Tucker et al. 2001), show only modest effects on PTSD symptoms. Recent 
literature reviews stress the importance of developing more effective medications and 
psychotherapeutic treatments for chronic PTSD (Foa et al. 2009, Stein et al. 2009).  
MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy is a novel 
approach to the treatment of PTSD that employs the psychoactive compound MDMA 
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as a catalyst of PTSD-specific psychotherapy itself. MDMA is a substituted phenylethyl-
amine first synthesized in 1912 by Merck, rediscovered in the 1970s by the chemist A. 
Shulgin and introduced to psychotherapy by the psychotherapist L. Zeff (Benzenhoefer 
and Passie 2006). Prior to the U.S. scheduling of MDMA as a drug of abuse in 1985, 
reports suggested it to be effective in psychotherapy (Metzner and Abramson 2001, 
Greer and Tolbert 1986). The first rigorously controlled clinical trials of MDMA-assisted 
psychotherapy in the treatment of chronic PTSD showed promising results (Bouso et 
al. 2008, Mithoefer 2011). The benefits of MDMA-assisted psychotherapy appear to be 
long-lasting (Mithoefer et al. In press). 
The current neurocircuitry model of PTSD postulates exaggerated and uncontrolled 
responses of the amygdala to trauma-specific cues as well as deficient top-down inhi-
bition of the amygdala by the ventromedial prefrontal cortex (vmPFC), orbitofrontal 
cortex and the hippocampus (Rauch et al 2006, Frewen 2006). MDMA increases activi-
ty in the vmPFC and decreases activity of the left amygdala (Gamma et al. 2000) possi-
bly reversing some of the above-mentioned abnormalities associated with PTSD. 
MDMA leads to a transporter-mediated release of serotonin and activation of the 5HT 
receptor and to a lesser extent to the release of dopamine and norepinephrine. Many 
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of the positive subjective effects can be attributed to the release of serotonin (Farre et 
al. 2007; Liechti et al. 2001), and as has been shown recently also of norepinephrine 
(Hysek et al. 2011). A main characteristic of the MDMA induced state is a positively 
toned cognitive-emotional state with reduced fear, possibly facilitating processing of 
traumatic material and better encoding of positive emotional experience. It is theo-
rized that therapeutic exposure to traumatic memories should be kept in an “optimal 
arousal zone” avoiding the extremes of overwhelming anxiety and other painful emo-
tions (that may lead to) dissociation on one hand and emotional numbing on the other 
(Ogden and Pain 2005). MDMA may widen this window enhancing affect tolerance and 
reducing numbing. The pronounced increases in levels of the neurohormone oxytocin 
under MDMA (Wolff et al. 2006) have been associated with the prosocial effects of 
MDMA (Dumont et al. 2009, Bedi 2009). The quality of the therapeutic alliance has 
been recognized as being crucial for the recovery from PTSD (Charuvastra and Cloitre 
2008) and the extensive release of oxytocin under MDMA has been postulated to be a 
prominent factor in improvement of the therapeutic alliance regularly observed in clin-
ical-therapeutic settings under MDMA (Johansen and Krebs 2009). The main postulat-
ed psychological effects relevant to the context of MDMA-assisted psychotherapy are 
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partially based on clinical impressions and also on clinical data from Vollenweider  et 
al.1998, Johanson and Krebs 2009, Passie and Dürst 2009 as shown in Table 1.  
This study was intended to serve as a proof of concept and to secondarily confirm the 
initial findings of the Mithoefer et al.’s (2010) study with a different therapist team. 
We examined safety and efficacy in an outpatient setting, that included overnight stays 
after each MDMA session in the clinic for safety reasons, in a small sample of twelve 
patients with chronic, treatment-resistant PTSD and providing a one year follow-up. A 
methodological challenge is the maintenance of the double-blind when using a pro-
foundly psychoactive substance like MDMA, since MDMA’s effects can be easily dis-
cerned by subjects and investigators. In the Mithoefer et al. study (2011), there were 
difficulties in maintaining the study blind using an inactive placebo control and it is 
possible that this difficulty affected study results. This study therefore attempted to 
address the question of whether the use of 25mg of MDMA as an “active placebo” 
could optimize blinding. We also hypothesized that three MDMA sessions were more 
effective than only two, and that reductions in PTSD symptoms would remain stable at 
the one year follow-up.  
Methods: 
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Recruitment and screening procedure 
Subjects were recruited for the study by a call for referrals from psychiatric hospitals, 
trauma counseling centers, psychiatrists and psychotherapists in the German speaking 
part of Switzerland. Prospective participants were first screened by a scripted tele-
phone interview to check for inclusion and exclusion criteria. Those who met criteria 
had an informational meeting with the investigator, which included the administration 
of the Clinician-Administered PTSD Scale (CAPS) to provide PTSD diagnosis. Written 
informed consent was then obtained from subjects by the investigators.  Medical eval-
uation included a medical history, standard physical examination, ECG, metabolic pro-
file, measurement of thyroid hormones, serum electrolytes, HIV, urinary drug and 
pregnancy tests (when appropriate). Subjects aged older than 40 years with a positive 
family history of coronary heart disease and/or presenting risk factors underwent a 
stress ECG. Psychiatric evaluation and confirmation of the PTSD diagnosis were con-
ducted by an independent rater using CAPS and Structured Clinical Interview for DSM 
(SCID) I and II. Enrollment began in September 2006 and ended in October 2009. A 
twelve-month follow-up was completed in January 2011. This study was approved by 
the ethics committee of the cantons of Solothurn and Aargau/Switzerland and was 
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conducted according to the regulatory guidance for protection of human subjects and 
relevant federal regulations and international standards. 
Subjects 
Twelve subjects (ten female, two male, mean age = 41.4, SD 11.2 years) meeting all 
inclusion and exclusion criteria were enrolled and completed the study. Two additional 
subjects discontinued treatment after the first experimental MDMA session. All sub-
jects who were enrolled met DSM-IV-text revision (TR) criteria for PTSD with treat-
ment-resistant symptoms as indicated by a CAPS score of > 50 and having previously 
undergone at least six months of psychotherapy and three months of treatment with 
an SSRI. Seven of twelve subjects had experienced one or more evidence based thera-
pies:  three subjects CBT, one exposure based therapy not specified, one EMDR, three 
anxiety management not specified and six subjects had had non-evidence based ther-
apies such as insight-oriented therapies. Many of the subjects had undergone multiple 
therapies and it was not possible any more to exactly identify in all cases the specific 
method that had been applied. Subjects were required to taper all psychotropic medi-
cation before entering the study. Gabapentin was allowed for pain control. Exclusion 
criteria included significant medical conditions, except for hypothyroidism under hor-
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monal replacement. Exclusionary psychiatric conditions were: history of psychotic ill-
ness, bipolar disorder type I, borderline personality disorder, dissociative identity dis-
order and substance abuse or dependence within 60 days of enrollment. Comorbid 
anxiety disorders, depression as well as eating disorders without active purging were 
allowed. Subjects who had taken MDMA on more than five occasions or less than six 
months prior to enrollment were excluded.  
One subject had previously used “ecstasy” on three occasions; one had consumed 
magic mushrooms (psilocybin) several times, the other subjects were completely naïve 
to psychedelic drugs. Two subjects (one female, one male) discontinued treatment 
after the first experimental MDMA session. Eleven of twelve subjects who completed 
the study also participated in the 12-month follow-up. One female subject did not 
complete the twelve-month follow up because she died six months after finishing the 
MDMA-assisted treatment from a brain metastasis arising from relapse of breast can-
cer; this subject had been in remission from her breast cancer for over ten years and 
had not been symptomatic at screening.   
Index traumata included physical and sexual abuse during childhood in six subjects, 
sexual assault in one, medical treatment in one, motor vehicle accident in two and life 
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threatening illness in two subjects. The mean duration of PTSD symptoms at enroll-
ment was 18.3 years (SD + 12). The mean duration of previous psychotherapeutic 
treatments was 85.8 months (SD + 71.4).  
Subjects were allowed to continue ongoing psychotherapy with outside/referring ther-
apists, but were not allowed to increase the frequency of ongoing treatments, or 
commence any new therapy until after the administration of outcome measures at 
two months after MDMA session #3. 
Description of study design 
In “Stage 1”, eight subjects were randomized in a double-blind manner to the full dose 
and four to the “active placebo” condition with three doses of MDMA administered in 
three all day-long MDMA-assisted psychotherapy sessions. Full dose consisted of 125 
mg followed 2.5 hours later by 62.5 mg MDMA; the “active placebo” dose consisted of 
25 mg followed 2.5 hours later by 12.5 mg MDMA. The 125 mg dose of MDMA was 
chosen on the basis of case reports of MDMA-assisted psychotherapy (Greer and Tol-
bert 1986, Widmer 1998) as well as on preliminary data obtained from the Mithoefer 
2011 pilot study. The dosages chosen for the low dose condition were selected on the 
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basis of their ability to produce minimal but detectable subjective effects (Grob et al. 
unpublished; Harris et al. 2002) and thus serve as an “active placebo”. The cumulative 
dose of 37.5 mg MDMA was not expected to produce a significant reduction in anxiety 
or a significant increase in access to emotionally upsetting material, though this dosage 
may produce slight alterations in perception, increased relaxation or tension (Harris et 
al. 2002). The study allocated a greater number of participants to the full dose condi-
tion (2:1) to better assess the safety of the full dose and to enhance recruitment ef-
forts.   
Outcome measures:  
Outcome measures included two measures of PTSD symptoms: 
The Clinician-Administered PTSD Scale (CAPS) is a DSM-IV based structured clinical in-
terview designed to quantify PTSD symptoms that has been determined to have excel-
lent psychometric properties of reliability and validity (Weathers et al, 2001). A vali-
dated German version of the CAPS was used (Schnyder et al. 2002), serving as screen-
ing and main outcome measure. 
The Posttraumatic Diagnostic Scale (PDS) (Foa et al. 1993; Foa et al. 1997) is a validat-
ed self-report measure assessing presence of PTSD symptoms as described in the DSM-
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IV serving as an additional outcome measure. An unvalidated yet widely used German 
version (Ehlers et al. 1996) was used in this study.  
 
The CAPS and SCID I substance abuse module were administered at baseline (T0), 
three weeks after MDMA-session #2 (T1); three weeks after MDMA-session #3 (T2; 
end of treatment); two (T3), six (T4) and twelve (T5) months after MDMA-session #3 
(follow-up). The PDS was administered one day after each MDMA session; three weeks 
after MDMA-session #3 (T2; end of treatment); two, six, and twelve months after 
MDMA-session #3 (T3, T4, T5; long term follow-up LTFU). All outcome measures were 
administered by a blinded, independent rater. Subjects were tested for drugs of abuse 
before MDMA sessions, and one time at random during Stage 1 and 2 and at each fol-
low-up testing. Pregnancy tests were performed in women of childbearing potential 
before each MDMA session. The blind was broken following assessment by the inde-
pendent rater after the end of Stage 1 treatment. Subjects assigned to the “active pla-
cebo” condition were offered an open label continuation of the study with the fully 
active dose of MDMA (“Stage 2”) with identical psychotherapy and assessment as in 
“Stage 1”. CAPS scores from the three weeks post MDMA #3 testing served as baseline 
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for “Stage 2”. All subjects in the “active placebo” condition in “Stage 1” proceeded to 
“Stage 2”.  Follow-up assessments consisting of the CAPS and PDS were completed two 
(T3), six (T4) and twelve (T5) months after the final MDMA-session #3.  
After preliminary analysis of data showed insufficient clinical response to the experi-
mental treatment in several full-dose subjects, an amendment to the protocol was 
obtained allowing for two additional sessions of MDMA-assisted psychotherapy for 
subjects deemed showing insufficient response, referred to as “Stage 3” and employ-
ing a dose of 150 mg MDMA and supplemental dose of 75mg MDMA unless contrain-
dicated for safety reasons. Response was considered clinically insufficient on the basis 
of the investigator’s and patients’ subjective impression of a lack of significant im-
provement and CAPS change scores (baseline to 2 months after the third experimental 
session) ≤ 15 points (Weathers 2001, Schnurr 2007), CAPS item #25 ≥ 3 and overall 
CAPS score still ≥ 50 points at outcome measurement two months after the third 
MDMA-session served as additional guidelines for the assessment of clinically insuffi-
cient response. All three conditions had to be fulfilled.  
MDMA 
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The MDMA (+/-3,4-methylenedioxymethamphetamine) was obtained from a supply origi-
nally synthesized by Lipomed AG/Switzerland. The investigational product (125, 62.5, 25 
and 12.5mg) was prepared in gelatin capsules of identical appearance and weight by the 
Laboratory Dr. Bichsel in Interlaken/Switzerland. Quality control and randomization was 
performed by R. Brenneisen, Department of Clinical Research, Phytopharmacology, Bioan-
alytics & Pharmacokinetics, University of Bern, Switzerland. 
Psychotherapy 
The treatment is described in the manual for MDMA-assisted psychotherapy in pa-
tients with PTSD (Mithoefer 2011, published online). Two preparatory sessions aimed 
at establishing a therapeutic alliance and preparing subjects for the MDMA experience 
preceded the first MDMA session. The MDMA sessions took place in group psycho-
therapy room at the first author’s clinic. Subjects arrived at nine a.m. After testing for 
drugs of abuse and females for pregnancy, session goals and intentions were recapitu-
lated. The MDMA was ingested at ten a.m. Subjects were instructed to remain reclin-
ing on the mattress, to focus attention inward, keep eyes closed as much as possible 
and to allow the inner process to unfold. The therapeutic tools used to guide the sub-
jects consisted of:   
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1. A program of music which was designed to support the subject’s experience by aiding 
relaxation and/or evoking and supporting deep emotions and the emergence of un-
conscious material (Bonny and Savary 1990, Spitzer 2002). 
2. MDMA-assisted psychotherapy is primarily focused on experiencing and is only to a 
lesser extent a verbal method during the MDMA sessions themselves. Discussions be-
tween therapists and participant take place only when needed. The therapeutic ap-
proach is generally non-directive, following and encouraging the MDMA-induced psy-
chological process.  
3. Focused body work was defined as bodily contact that employs nurturing touch (e.g. 
hand-holding) and touch aimed at intensifying and thereby releasing body tension and 
pain by giving resistance for the subject to push against. It is always performed with 
explicit consent from the subject and respecting individual boundaries and vulnerabili-
ties. 
The therapists (one male and one female) were present during the entire session. 
MDMA-sessions lasted approximately eight hours, after which the subjects were of-
fered a light meal and a previously designated support person (e.g. spouse) arrived to 
stay with them overnight at the clinic. A non-drug psychotherapy session took place 
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the morning after each MDMA experience, followed by two sessions one week apart 
aimed at ensuring the integration of the experiences from the MDMA-sessions. The 
therapist attitude was supportive, validating the MDMA experience and facilitating 
understanding and emotional clearing. Following each MDMA session, the subjects 
were contacted via telephone by one of the therapists on a daily basis for one week in 
order to assess the subject’s psychological well-being and monitor drug after-effects. 
Subjects received a total of twelve non-drug psychotherapy sessions. Additional ses-
sions in case of excessive distress were limited to two after each MDMA session. 
 
Further Assessment and Safety Measures 
Subjects’ blood pressure (BP) and heart rate (HR) were measured 15 and five minutes 
before ingestion of the MDMA, afterwards every half-hour for four hours and then 
every hour until termination of the session. Body temperature was measured 15 
minutes before MDMA administration and hourly until termination of the session. The 
degree of psychological distress was monitored repeatedly during the course of each 
MDMA session with a one-item visual analog scale, the Subjective Units of Distress. 
The participant’s beliefs concerning condition assignment were collected during the 
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non-drug psychotherapy session the day after each MDMA session. The therapists col-
lected any spontaneously reported reactions over a seven-day period starting on the 
day of each experimental session. 
Statistical Analysis 
CAPS and PDS scores were analyzed by nonparametric analysis of variance (ANOVA) 
using an F1-LD-F1 model (Brunner and Langer (1999), Brunner et al. (2002)) with the 
experimental intervention condition (full dose MDMA versus “active placebo” MDMA) 
serving as a between-group factor and time of measurement serving as a within-
subjects factor. Given an insufficient number of participants in “Stage 2” for formal 
analysis, scores were compared across the two stages to see whether “Stage 2” scores 
were reduced compared to “Stage 1” scores. The Wilcoxon Signed-Rank-Test for paired 
data was used to analyze whether a third MDMA session improved CAPS scores com-
pared to only two MDMA sessions.  Group comparisons of vital signs pre- to post-
session (excluding data from the high dose group due to insufficient sample size) were 
performed by first averaging the values for each subject over the three sessions to ob-
tain an “average” day and then calculating a nonparametric 95% confidence interval 
covering the true median of the differences (pre- to post-session). To compare the 
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magnitude of the difference between the maximally observed value and the baseline 
value between treatment groups, a similar approach as above was chosen: To show 
that the values of the increase are higher on average in the full dose group than in the 
placebo group, a lower confidence bound B for the difference of increase, such that 
the true value of increase (full dose) – increase (“active placebo”) is as least as big as B 
with a confidence of 95%, was computed. Given the small sample size no adjustments 
for covariates were made and the study had only sufficient power to detect large ef-
fects. Therefore, there was no adjustment for multiple testing; unadjusted exact p-
values and confidence intervals were reported instead. Results were considered signif-
icant when p < 0.05. Trends were also reported when p < 0.1. The F1-LD-F1 models 
were computed with SAS 9.1, all other analyses were performed with the statistics 
program R 2.7.1. 
Results: 
Efficacy: Figure 1 shows the course of CAPS and PDS scores over time in the two 
groups. Interestingly, the average CAPS scores in the “active placebo” group increased 
slightly from T1 to T2. The three interaction relative treatment effects (RTE) T0-T2 for 
total CAPS scores in the full dose group showed a distinct decrease in CAPS scores with 
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time compared to the active placebo group in the ANOVA but narrowly missed statisti-
cal significance (p=0.066). On average, CAPS scores decreased 15.6 points (23.5%) in 
full dose subjects. There was a significant simple effect of time in the full dose group 
(p=0.002), meaning that the time effect was significant only in the full dose group. The 
simple time effect for the active placebo group was not significant (p=0.475). For the 
other two models T0 vs. T1 and T1 vs. T2 group and time effects and interaction were 
not significant. PDS scores decreased in the full dose group compared to an increase in 
the “active placebo” group. There was a significant interaction effect of group and time 
(p=0.014).   
A Wilcoxon Signed Rank test for paired data was performed to test whether three 
MDMA sessions were more effective than only two sessions. There was a significant 
difference in CAPS scores (p=0.016, exact p-value to account for ties) between the two 
time points T1 and T2.  
The median prior psychotherapy treatment times of the „active placebo“and the full dose 
group were 123 and 39.9 months. A comparison of the two distributions using the two-
sample Wilcoxon rank sum test yielded a two-tailed p value of 0.154. 
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Safety: There were no serious drug-related adverse events and medical intervention 
was not required during or following MDMA sessions. 
Rescue medication: Zolpidem for insomnia was offered for the first nights after MDMA 
sessions but was administered on only one occasion. Most subjects refused sleep med-
ication, frequently commenting that lying awake was not experienced as being dis-
tressing but an opportunity to reflect on the still ongoing inner process. Lorazepam for 
anxiety/distress related to the processing of the traumatic memories was administered 
in six out of nine subjects after ten out of 56 full dose or 150 mg MDMA sessions, typi-
cally during the week after MDMA sessions, with five of these six subjects having been 
on antidepressants and/or benzodiazepines at enrollment. In all cases single doses of 
1-2mg lorazepam reduced the anxiety or distress adequately. Only one subject with no 
psychotropic medication at enrollment required lorazepam on one occasion. In the 
“active placebo” group lorazepam was administered to two of five subjects after three 
low dose MDMA sessions. Both had been treated with antidepressants and/or benzo-
diazepines at enrollment. The other three active placebo subjects did not need any 
medication nor had they had any psychotropic medication at enrollment. Except for 
the subject who was subsequently diagnosed with a prefrontal brain metastasis and 
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who experienced a panic attack, the anxiety that required medication was related to 
the PTSD. Acetaminophen or mefenamic acid (in two subjects with a history of head-
ache refractory to acetaminophen were administered short term for headache follow-
ing MDMA sessions. 
Spontaneously reported reactions: See Table 3. The most commonly reported reactions 
on the day of the experimental session were moderate insomnia (125mg: 43%, 150mg: 
50%), loss of appetite and restlessness in subjects receiving 125mg MDMA, and head-
ache, moderate insomnia (31%) and loss of appetite in subjects receiving 25mg 
MDMA. Insomnia and loss of appetite were the most commonly reported reactions in 
both conditions. Restlessness, tight jaw, thirst and feeling cold were commonly report-
ed reactions in the full dose group that were minimally reported in the active placebo 
group. Dizziness, headache and impaired gait/balance were also frequently reported in 
both groups. Most reactions resolved when drug effects diminished. Loss of appetite, 
difficulty concentrating, anxiety, and headache persisted beyond this window to 24 
hours, but were self-limiting. 
Physiologic data: See Table 4. For both groups temperature values tended to be signif-
icantly higher pre- to postsession within the range of between 0.97 and 0.46 degrees 
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Celsius. In the full dose group, systolic BP and HR did not change significantly (albeit 
just narrowly which may be due to underpowering). The comparison of the difference 
between the maximally observed and the baseline value between conditions showed 
that all lower confidence bounds B were negative meaning the increase in any of the 
physiological parameters was not significantly higher in the full dose than in the place-
bo group.   
Additional psychotherapy sessions: Additional integrative psychotherapy sessions were 
conducted as per protocol in situations of excessive distress or other issues following 
MDMA sessions. Eight out of thirteen subjects who received full dose either in the ini-
tial randomization or in the “Stage 2” crossover group required a total 21 additional 
sessions with no more than four additional sessions per subject and stage (mean 1.6 
per subject). In the “active placebo” group (N=5) four additional sessions were provid-
ed to the above-mentioned two “active placebo” subjects exhibiting excessive distress 
(mean 0.8 per subject). One additional session was conducted in “Stage 3” (mean 0.3 
per subject) 
Clinical Response and LTFU: Clinical response as defined above was observed in four 
out of eight subjects in the full-dose group with all of them still fulfilling PTSD criteria 
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but with a reduction in severity from severe to mild (CAPS score 20-39) (n=3) or mod-
erate (CAPS score 40-59) (n=1) PTSD.  
Three full-dosage subjects met criteria for being non-responders and were enrolled in 
“stage 3” with either a full or higher dose of MDMA (two full-dose sessions, two high-
dose sessions and two high dose sessions followed by a lower supplemental dose). The 
dosages were chosen on the basis of clinical judgment. The additional sessions did not 
lead to any further improvements in CAPS scores (mean CAPS score change 0.3 points). 
As a result, no further subjects were enrolled in “Stage 3”. 
In the “active placebo” group all four subjects failed to respond to the treatment with 
two subjects showing higher CAPS scores and a slight clinical deterioration. In the 
“Stage 2” crossover group, all four subjects responded to the treatment: two of four 
subjects no longer fulfilled PTSD criteria and two had improved but still had moderate 
PTSD. At the one-year follow-up, CAPS scores had decreased by a mean of 24 points 
(35%) compared to baseline in the full-dose group and 35 points (52%) in the crossover 
group with nine subjects showing a significant clinical improvement. The majority of 
subjects continued their previous or another psychotherapy or medication during this 
time. Also at LTFU, five of twelve subjects no longer met the diagnostic criteria for 
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PTSD, two had mild PTSD, four had moderate PTSD and one had died of a cause not 
related to the study. One of four subjects on disability and three fit for limited em-
ployment at baseline had returned to work fulltime at the 1-year follow-up. 
Blinding: The investigator’s guesses on the 14 subjects’ condition assignments were 
correct in eight full dose subjects (including one drop-out) and uncertain in one full 
dose subject. They were also correct in 2 active placebo subjects, whereas their guess-
es were incorrect in one and they were uncertain in two active placebo cases (includ-
ing one drop-out). Thirteen subjects provided guesses concerning condition assign-
ment: The full dose subjects’ guesses were correct in four, uncertain in two and incor-
rect in two cases, with uncertainty defined as changing their condition assignment 
guess over time. Subjects in the “active placebo” group guessed correctly in two, were 
uncertain in one case (drop-out) and incorrect in two cases. Combining all the guesses 
for subjects and clinical investigators and ignoring the level of certainty shows that 
there were a total of 37 guesses, with 22 (59%) correct and 15 (41%) incorrect. For the 
24 guesses of full dose sessions, 16 (66%) were correct and 8 (34%) were incorrect, and 
for the 13 guesses of low dose sessions, 6 (46%) were correct and 7 (54%) were incor-
rect. Since there were only two doses in the study producing a 50% chance of a correct 
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guess by chance alone, the authors conclude that the study blind was successfully 
maintained based on these results. 
Discussion: 
This small randomized, blinded pilot study of MDMA-assisted psychotherapy in a 
population of subjects with chronic, treatment refractory PTSD as encountered in daily 
psychiatric practice demonstrates that this novel treatment method can be safely ap-
plied in an outpatient setting (including an overnight stay for safety reasons after each 
MDMA session) with no drug-related serious adverse events. Cardiovascular effects 
and body temperature increases were similar to those reported in the literature and 
did not require medical intervention. The spontaneously reported reactions occurred 
in the expected range seen in the literature, and were generally mild and well tolerat-
ed. A comparison of the safety profiles between 25 mg and 125 mg did support that 
the 125 mg dose was associated with more reactions in general. Efficacy failed to reach 
statistical significance (p= 0.066) as measured by the primary outcome measure, the 
CAPS, whereas self-assessment of the subjects’ PTSD symptoms as measured by the 
self-report questionnaire PDS showed a significant reduction (p= 0.014). Three experi-
mental MDMA sessions were significantly more effective than only two (p= 0.016). 
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Further improvement over the one-year follow-up time was unexpected (CAPS score 
reduction of 35% in “Stage 1” full dose subjects and 52% in “Stage 2” crossover full 
dose subjects, with nine out of eleven showing clinical response). Since all participants 
at 12-month follow up had received full-dose MDMA in either “Stage 1” or “Stage 2”, 
comparisons by condition were not possible at the 12-month follow-up. Four subjects 
had changed or begun a new therapy during follow-up, two received a SSRI for relapse 
of depression and one had participated in stage 3. It is therefore unclear to which de-
gree these findings at the 12-month follow-up can be attributed to the experimental 
treatment.  
An unforeseen clinical observation in the “active placebo” group showed that there 
were two distinct types of reactions to the low dose of MDMA: three of the subjects 
(including one drop-out) experienced similar but milder psychotherapeutic processes 
to those of the full dose subjects, including spontaneous recall and reliving of traumat-
ic memories along with intensified negative emotions but without the typical positive 
and integrative effects of the full dose MDMA-state, suggesting a partial activation of 
the MDMA-induced state. This state of partial activation (spontaneous recall of trauma 
but without maximum fear reduction) resembles clinical observations of the early 
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stages of the MDMA experience in many of the full-dose subjects. Consequently, the 
resulting (more stressful) form of exposure to the traumatic memories required more 
support from the therapists during and between MDMA-sessions, was more trying for 
the subjects, and led to the drop-out of one subject who felt overly stressed by the 
process. The other two “active placebo” subjects showed no or only slight (pleasant) 
changes in perception (i.e. being touched by music) and relaxation (i.e. feeling light), 
which wore off after one hour.  
Interestingly, we did not find a placebo response as has been observed in other psy-
chopharmacological studies of PTSD (Davidson 2001, Marshall 2001, Tucker 2001, 
Mithoefer 2011). This and the observed partial activation of the MDMA state in three 
of five subjects of the “active placebo” group indicate that psychotherapy with even a 
low dose of MDMA may influence the course of PTSD and possibly interferes with the 
placebo effect in some subjects. We postulate that the unfolding of the different as-
pects of the typical MDMA state in a psychotherapeutic setting (see Table 1) is a func-
tion of dose and time.  
Additional medication for sleep disorders was needed on only one occasion which is 
surprising given the fact that many of the subjects experienced chronic insomnia due 
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to their PTSD and had taken sleep medications in the past and noting that insomnia is a 
common side effect of MDMA. This result contrasts distinctly to the results of the 
Mithoefer 2011 study which used an inactive placebo. We interpret this finding as an 
indication of the enhanced tolerance of distress and aversive emotional states includ-
ing insomnia under and following MDMA and conclude that sleep medication should 
be given only on request. Despite this effect on the tolerance of insomnia, the pro-
longed and intensive exposure to traumatic material inherent to this treatment meth-
od can temporarily cause distress and anxiety in the integration phase. The increase in 
distress may require additional medication with benzodiazepines and/or additional 
psychotherapy sessions. Benzodiazepines were used as little as possible in order to 
avoid suppressing the ongoing integration process. It is noteworthy that most of the 
subjects requiring benzodiazepines after the MDMA intervention had been treated 
with antidepressants with anxiolytic effects and/or benzodiazepines at enrollment and 
that only one subject who had been free of anxiolytic or antidepressant medication at 
enrollment received a benzodiazepine during the study. We postulate that the need 
for benzodiazepines is more likely to be related to a predisposition for anxiety rather 
than to direct MDMA effects, therefore is not a safety concern.  
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It is difficult to interpret the discrepancy between the results of this study and that of 
Mithoefer and colleagues in terms of the primary outcome (mean CAPS change score 
53.7 under MDMA vs. 20.5 points under placebo (p=0.015), clinical response (>30% 
CAPS score reduction) 83% vs. 25%), given that they followed a similar design, em-
ployed the same main outcome measure, administered only two MDMA sessions and 
noted a distinct placebo effect. We presume that other factors could have influenced 
outcome such as cultural differences, independent rater differences, therapist differ-
ences, or the sample possibly including more cases with a higher degree of overall se-
verity of the illness not captured by the employed screening and diagnostic measures 
(i.e. personality structure, attachment style, etc.). However, with the small sample size 
the difference could also have been due to chance.  
Limitations: This exploratory study intended to investigate the safety of the method 
and to serve as proof of concept was underpowered as is acceptable for such phase II 
studies. Further goals of this study were to test for efficacy and to further develop an 
optimal research protocol for phase III studies addressing two basic challenges in the 
investigation of this novel method: the first challenge is that this method is a combina-
tion of a psychotherapeutic intervention and a catalyzing psychopharmacological 
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treatment. To date there are no recognized and standard methods for the investiga-
tion of this type of combined therapy and only one rigorously controlled trial has been 
previously reported (Mithoefer et al 2011). MDMA is not just an augmenting “add-on” 
medication but rather a catalyst that dramatically influences the psychotherapeutic 
process itself. This makes it virtually impossible to distinguish pure drug effects from 
psychotherapeutic effects. The second challenge is that current research standards 
require the use of double blind RCTs for the assessment of the psychopharmacological 
part of the method with the difficulty of ensuring an acceptable double-blind. Phase 1 
studies investigating MDMA or other psychoactive compounds such as psilocybin have 
used substances such as methylphenidate, d-amphetamine or nicotinic acid as sub-
stances that may mimic some of the effects of the study drug and therefore may be 
effective as active placebos. Our findings suggest that subjects were successfully blind-
ed to study condition using low dose MDMA as an active placebo and that the blind 
occurred in both conditions. Clinical investigators were less blinded to subject condi-
tion assignment than subjects but the blind was still sufficiently effective in clinical 
investigators, showing that a small dose of MDMA used as an “active placebo” im-
proved the blinding compared to the study by Mithoefer et al (2011).  
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Prototypical MDMA effects are expected only at doses over 80mg (Bedi et al. 2009). 
Three of five active placebo subjects seemed to show partial MDMA effects at much 
lower doses which enhanced the blind. However the low dose turned out to be less 
well tolerated psychologically and required more therapist interaction than the fully 
active dose. A study addressing this question is currently underway (NCT01211405). A 
further weakness was the lack of power for the statistical analysis for differences of 
gender and country of origin; most subjects were females and Europeans. It is difficult 
to generalize from relatively homogenous and small samples. Differences in the dura-
tion of previous therapy between “active placebo” and full dose group were not signif-
icant (p=0.083). In the light of the two drop-outs coming from other cultures (Turkey, 
South Africa), these possible covariates deserve attention in future studies. The imbal-
ance between the number of “active placebo” and full dose subjects is also a limita-
tion. 
Adherence to the manual and inter-rater reliability were tested only post-hoc (data not 
presented here). The adherence raters viewing session videos from this study and the 
study by Mithoefer et al (2011) noticed a few areas where our therapy differed some-
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what from the manual, in that our approach was considered more directive in some 
places. Whether this had any impact on outcomes will require additional research.  
Conclusions: 
From a clinical point of view we recommend that future studies include three instead 
of only two preparatory sessions to strengthen the therapeutic relationship before 
administering MDMA. The observed 100% response rate of the crossover subjects in 
“Stage 2”, compared to the 50% response rate of the subjects receiving full dose 
MDMA in “Stage 1”, suggests that strengthening the therapeutic alliance does contrib-
ute to enhancing treatment outcomes. Future studies should also find a way to mini-
mize additional psychotherapy sessions, as this could be a potentially confounding fac-
tor. 
In summary, MDMA-assisted psychotherapy was safely administered, with no drug-
related serious adverse events, in a small sample of treatment resistant patients suf-
fering from chronic PTSD. The approach did not, however, produce significant symp-
tom reductions. Further research into MDMA-assisted psychotherapy is warranted to 
verify the results of the Mithoefer 2011 study. 
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Figure 2: 
 
 
  
 
 
 
 
 
 
 
CAPS mean total scores by group for time TO-T2 (SD) 
TO: Baseline < 4 weeks before MDMA and after         
discontinuation of psychotropic  medication  
        Active Placebo: 63.4 (7.9)  Full Dose: 66.4 (13.6) 
T1: 3 weeks post MDMA-session 2 
Active Placebo: 60.0 (6.8)  Full Dose: 63.0 (17.8) 
T2: 3 weeks post MDMA-session 3  
(end of treatment)  
Active  Placebo: 66.5 (7.6)  Full Dose: 50.8 (19.7) 
CAPS Change scores (SD):  
T0-T1: Active Placebo: -3.3 (9.9)   Full dose: -3.4   (12.0) 
T1-T2: Active Placebo:  6.5 (10.3) Full dose: -12.2 (8.1) 
T0-T2: Active Placebo: -3.2 (15.3) Full dose: -15.6 (18.1) 
PDS mean scores by group for time TO-T2 (SD) 
TO: Baseline < 4 weeks before MDMA and after         
discontinuation of psychotropic  medication 
        Active Placebo: 23.5 (1.9)  Full Dose: 30 (6.3) 
 
T2: 3 weeks post MDMA-session 3  
(end of treatment)  
Active Placebo: 30.8 (6.2) Full Dose: 21.4 (11.9) 
 
Changes scores T0-T2 (SD):   
Active Placebo: 7.3 (6.2)           Full dose: -8.6  (13.0) 
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Figure 1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 30 ) 
Excluded  (n= 16 ) 
♦ Not meeting inclusion criteria at  
telephone screening (n=9) 
♦ Declined to participate (n= 5) 
♦ Not meeting inclusion criteria at full 
screen (n=2) 
 
♦ Analysed Stage 1 (double blind) (n=8 ) 
♦ Excluded from analysis (n=0) 
 
♦ Follow-up analysis (n=7) 
♦ Lost to follow-up (deceased) (n=1) 
 
Allocated to 3 full dose MDMA sessions and 
12 non-drug  therapy sessions (n= 9) 
♦ Received allocated intervention (n=8) 
♦ Dropped out (n=1) (withdrew because of    
AE after MDMA session 1) 
♦ Elected to enter open-label arm with high 
dose (stage 3) (n=3) 
♦ Follow-up analysis (n=4) 
♦ Lost to follow-up (n=0 ) 
 
Allocated to 3 “active placebo” MDMA sessions  
and 12 non-drug psychotherapy sessions (n=5 ) 
♦ Received allocated intervention (n= 4 ) 
♦ Dropped out (n=1) (withdrew because of AE 
after MDMA session 1) 
♦ Elected to enter open-label arm (stage 2) 
(n=4) 
♦ Analysed  Stage 1 (double blind) (n=4) 
♦ Excluded from analysis (n=0 ) 
 
 
Randomized (n=14  ) 
Open label arm (stage 3) 
Allocated to 2 additional high dose MDMA ses-
sions and 7 non drug psychotherapy sessions 
(n=3)  
(protocol amendment) 
♦ Received allocated intervention (n=3) 
         After T5: n=2 
         After T3: n=1 
Open label arm (stage 2) 
Allocated to 3 full dose MDMA sessions and  
12 non-drug psychotherapy sessions 
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Table 2:  Participant characteristics 
Characteristic  Full dose group Placebo group Total 
  n=8 n=4 n=12 
Gender Female 7 (87%) 3 (75%) 10 (83%) 
 Male 1 (12%) 1 (25%) 2   (16%) 
Mean age (SD)  Range 23 – 67y 42.1 (12.8) 40.0 (6.2) 41.4 (11.2) 
Country of origin Study completers CH: 7, F: 1 CH: 4 CH: 11, F: 1       
 Drop-outs  TR: 1 ZA: 1                  
Marital Status Single 3 (37%) 2 (50%) 5 (41%) 
 Married/living with partner  2 (25%) 2 (50%) 5 (41%) 
 Divorced/separated 3 (37%) 0 (0%) 4 (33%) 
Work status On disability 4 (50%) 1 (25%) 5 (42%) 
 Fit for limited employment 2 (25%) 1 (25%) 3 (25%) 
 Working fulltime 1 (13%) 2 (50%) 3 (25%) 
 Retired 1 (13%) 0 (0%) 1 (8%) 
History of abuse/dependency Alcohol 1 (13%) 0 (0%) 1 (8%) 
 Cannabis 1 (13%) 1 (25%) 2 (17%) 
Prior drug use MDMA (# subjects) 0 1 (3 occasions) 1 
 Psilocybin (# subjects) 1 0 1 
Mean # years duration of PTSD (SD) Range 3 - 40y 16.4 (10.9) 22.3 (12.1) 18.3 (12.0) 
Mean # months of prior psychotherapy (SD)  Range 22 - 240m 39.9 (73.3) 123 (60.6) 85.8 (71.4) 
Comorbid disorder Unipolar depression 7 (88%) 3 (75%) 10 (83%) 
 Panic disorder 0 (0%) 1 (25%) 1 (8%) 
 Eating disorder 1 (13%) 0 (0%) 1 (8%) 
 Seasonal affective disorder 1 (13%) 1 (25%) 2 (17%) 
 Dysthymia 1 (13%) 0 (0%) 1 (8%) 
Index trauma Childhood sexual abuse 4 (50%) 2 (50%) 6 (50%) 
 Sexual assault 1 (13%) 0 (0%) 1 (18.%) 
 Accident 1 (13%) 1 (25%) 2 (17%) 
 Medical treatment 1 (13%) 0 (0%) 1 (28%) 
 Life-threatening illness 1 (13%) 1 (25%) 2 (17%) 
Medication for PTSD at enrollment  4 (50%) 2 (50%) 2 (50%)   
 
                                   CH: Switzerland; F: France; TR: Turkey; ZA: South Africa 
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Table 1: Psychological effects of MDMA in the context of psychotherapy 
Category MDMA-induced state Psychotherapeutic implication 
Mood/Affect Mild euphoria  
Anxiety and fear ↓  
Enhanced perception of and intensified feelings  
Affect tolerance↑ 
Positive and fearless emotional state of well-
being 
Emotional avoidance↓  
Tolerance and processing of difficult emotions 
(“window of tolerance”)↑ 
Cognition/ 
memory 
More imaginative and associative  
Contemplativeness↑  
Recall and tolerance of traumatic memories↑  
Recall of relevant traumatic memories↑ 
Prolonged spontaneous exposure to traumatic 
memories  
Cognitive restructuring 
“simulation of alternative behavior” 
Attachment-/ 
interpersonal 
Behaviour 
Social fears and defensiveness↓  
Social approach behaviour↑ with empathy,  openness, trust, 
feelings of being connected  to others↑  
Cuddling and need for touch↑  
Improvement of therapeutic alliance  
Rebuilding of trusting relationships 
Defensiveness and isolation↓ 
Self Self-esteem ↑  
Self-acceptance↑  
Grounding/centering↑ 
Consolidation of self↑ 
Body Release of muscular tension  
Analgesia  
Sensuality↑  
Release of tension and reduction of somatic 
symptoms 
Positive body image  
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